Navigation Links
Bradmer announces 2008 first quarter operational and financial results
Date:5/9/2008

TSX: BMR

TORONTO, May 9 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a clinical oncology company specializing in the development and commercialization of cancer therapies, today announced its 2008 first quarter operational and financial results.

Operational Highlights

During the three months ended March 31, 2008, the Company achieved the following steps in preparation for the upcoming multi-center Phase III trial and subsequent planned commercialization for its lead drug Neuradiab, a treatment for glioblastoma multiforme, the most deadly form of brain cancer:

- Prepared and submitted the Company's drug manufacturing data package

to the FDA. The submission is currently under review. After

completion of the review and satisfactory resolution of any further

requests of the FDA, if any, Bradmer will submit a clinical update to

its Investigational New Drug (IND) application and proceed with the

launch of the planned Phase III trial.

- Entered formal contracting and approval processes with more than 30

U.S. clinical trial sites, in line with previously stated site

recruitment goals.

- Appointed Robert Tessarolo, Vice-President Sales & Marketing, Biovail

Pharmaceuticals Canada to the Board of Directors

- Hired Jukka Karjalainen, M.D., Ph.D. as Chief Operating and Medical

Officer.

"We have made significant progress toward the start of our planned multi-center Phase III trial of Neuradiab in patients with glioblastoma. Our submission to the FDA focuses specifically on reducing risk in the critical areas of manufacturing, regulatory and clinical operations," said Alan M. Ezrin, Ph.D., President and Chief Executive Officer of Bradmer. "We have successfully completed all aspects of workup required to start this trial and await the review of the FDA. We look forward to enrolling
'/>"/>

SOURCE Bradmer Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine news :

1. Bradmer announces new additions to management team
2. Bradmer announces 2007 fourth quarter and fiscal year operational and financial results
3. Notice of Bradmer Pharmaceuticals Conference Call
4. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
5. Bradmer to present at the 10th Annual BIO CEO & Investor Conference
6. Bradmer announces additions to Scientific Advisory Board
7. Bradmer Medical Isotope Supply For Phase III Trial Secure
8. Bradmer to present at Rodman & Renshaw Healthcare Conference
9. Bradmer provides Phase III Neuradiab trial update and guidance
10. Bradmer announces management changes
11. Shengtai Pharmaceutical, Inc. Announces Conference Call to Discuss Third Quarter Results of Fiscal Year 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2014)... (PRWEB) September 01, 2014 The B-cell ... growth across six major markets (the US, France, Italy, ... 2013 to $5.41 billion by 2018. , The competitive ... France, Italy, Germany, Spain and the UK is poised ... Disease management of the four largest B-cell NHL indications, ...
(Date:9/1/2014)... September 2014: Permanent atrial fibrillation (AF) doubles the risk ... in more than 6 000 patients presented at ESC ... findings suggest that a simple clinical assessment of the ... stroke risk. , Ischaemic stroke is the second cause ... million deaths and many more disabled patients each year. ...
(Date:9/1/2014)... BCC Research ( http://www.bccresearch.com ) reveals ... AND GLOBAL MARKETS , the global market for blood-brain ... is expected to reach $38.7 million in 2014. This ... 2019, which is equivalent to 64.9% compound annual growth ... (RMT) segment is forecasted to grow at a CAGR ...
(Date:9/1/2014)... (PRWEB) September 01, 2014 Parties involved ... ahead to the litigation’s status conference in September, where ... be discussed in the Eastern District of Pennsylvania, Bernstein ... of status conferences posted on the Court’s website, the ... 2014 at 10:00 a.m. This is the latest of ...
(Date:9/1/2014)... September 01, 2014 Ontraport , ... marketers that was developed to automate the small intricacies ... attention of Shane Michaels, prompting an investigative review. ... daily duty of managing all of the small details ... quite overwhelming,” reports Michaels. “That’s why Ontraport has become ...
Breaking Medicine News(10 mins):Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Permanent AF doubles risk of stroke compared to paroxysmal AF 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 2Health News:Global Market for Blood-Brain Barrier (BBB) Technology to Reach $471.5 Million in 2019; Highest CAGR Growth in Latin American Market With 10.5% 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 2Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 3Health News:Tylenol Lawsuit News: Bernstein Liebhard LLP Notes Upcoming Status Conference in Pennsylvania Litigation 4Health News:Ontraport: Review Exposes Automated Platform for Online Marketing Management 2
... can lay siege on the victim's disposition and way of ... of coolness can act as an effective pain// reliever. Scientists ... that enable feelings of coolness, and bring immense relief to ... for improved treatment measures for people suffering long-term pain, as ...
... President of the Canadian Medical Association (CMA) said that Canadian ... health of their own children// although in general they rated ... to a survey carried out by Ipsos-Reid, commissioned by the ... kids aged 2-17 are obese/overweight, however only 9% of Canadian ...
... are high during air travel, and not with other forms of ... blood clots can from during any form of travel where the ... has revealed that traveling for more than four hours by air, ... This was substantiated when the research team analyzed 2000 people, who ...
... phobia or fear of needles can be overcome by ... to researchers at the University of New Mexico's// (UNM) ... needles can impact the care a patient receives. ... of needles, whereas some adults avoid the doctor's office ...
... institutions claim to have found that nearly 19% of ... to a direct// result of war. ,Now ... would get the proper treatment necessary. Their fears see ... now mental health treatment from the Department of Veterans ...
... every month for several problems ranging from arthritis to ... enrolled// in Medicare Part D, the new federal prescription-drug ... plan paid for most of their drugs, minus $20 ... coverage stopped. Donna was told by a pharmacist that ...
Cached Medicine News:Health News:American War Veterans Not Receiving Enough Care For PTSD 2Health News:Many American senior citizens fall into the “Doughnut Hole” 2Health News:Many American senior citizens fall into the “Doughnut Hole” 3Health News:Many American senior citizens fall into the “Doughnut Hole” 4
(Date:8/29/2014)... , Aug. 29, 2014  A Boston Scientific ... study on stent removability and preliminary long term ... published in the August issue of the peer-reviewed ... 1 is being conducted in 11 countries ... covered self-expanding metal stents (FCSEMS) after extended indwell ...
(Date:8/29/2014)... PLEASANTON, Calif. , Aug. 29, 2014 ... leader in device-based mechanical circulatory support therapies to save, ... be participating in the 2014 Morgan Stanley Global Healthcare ... F. Burbach , President and Chief Executive Officer, will ... p.m., Eastern Daylight Time (9:55 a.m., Pacific Daylight Time). ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Cancer Therapeutics Market & Pipeline Insight 2014" report ... developed to prevent and eradicate the prevalence of cancer ... are confined to low specificity, safety and large number ... for a better solution. It has been discovered that ...
Breaking Medicine Technology:Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 2Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 3Boston Scientific Study Published In Gastroenterology Reports Successful Management Of Benign Biliary Strictures With Fully Covered Metal Stents 4Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2
Inquire...
... injectable implant that contains microparticles ... biodegradable, synthetic polymer from the ... prior to use by the ... Injection, USP (SWFI) to form ...
Minimizes imperfections and reduces the visible appearance of cellulite and stretch marks. This formula refines uneven skin texture and improves skin firmness and elasticity to leave you with skin yo...
... This new Suction Massage System has been ... areas, such as thighs, buttocks and hips. ... the lymph system, mobilizing excess fluids in ... Initially, we recommend using CELLUSSAGE daily, for ...
Medicine Products: